US20220096407A1 - Composition for inhibiting respiratory viruses and respiratory virus prevention and treatment method - Google Patents
Composition for inhibiting respiratory viruses and respiratory virus prevention and treatment method Download PDFInfo
- Publication number
- US20220096407A1 US20220096407A1 US17/034,787 US202017034787A US2022096407A1 US 20220096407 A1 US20220096407 A1 US 20220096407A1 US 202017034787 A US202017034787 A US 202017034787A US 2022096407 A1 US2022096407 A1 US 2022096407A1
- Authority
- US
- United States
- Prior art keywords
- acetic acid
- inhalant
- drugs
- respiratory
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention belongs to the technical field of biomedicine, and specifically relates to a composition for inhibiting respiratory viruses and a respiratory virus prevention and treatment method.
- respiratory viral infectious disease has complex etiology and high viral variability, which is prone to outbreaks in the population.
- viruses that can cause respiratory infections, which can be divided into RNA viruses and DNA viruses.
- the most common pathogenic viruses include influenza viruses, parainfluenza viruses, respiratory syncytial viruses, adenoviruses, rhinoviruses and coronaviruses.
- SARS coronavirus SARS coronavirus
- H5N1 human avian influenza A virus and 2009 novel H1N1 influenza A virus.
- Novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19) refers to the pneumonia caused by the 2019 novel coronavirus infection.
- the structure of the novel coronavirus includes a protein coat and a single-stranded RNA carrying genetic materials. This simple structure reduces the difficulty of replication of the novel coronavirus and increases the spread of the virus. The single strand makes the novel coronavirus more likely to mutate, thereby increasing the difficulty of drug treatment.
- the main transmission routes of the novel coronavirus include respiratory droplet transmission, contact transmission, aerosol and fecal-oral transmission. Epidemiological investigations show that people of all ages may be infected, and most victims are adults, among whom the elderly, the weak and the sick seem to be more likely to be infected.
- Respiratory viral infections are clinically very common, but there are few corresponding therapeutic drugs.
- Commonly used clinical antiviral drugs mainly include oseltamivir, amantadines, ribavirin, ganciclovir and Chinese patent medicines containing Scutellaria baicalensis or andrographolide, and the main prevention methods for respiratory viral infections are vaccine prevention, personal hygiene, disinfection of the external environment and the like.
- the current treatment and prevention drugs cannot fully meet the current needs for the treatment of respiratory viral infections, and the speed of research and development of related drugs is far lower than the speed of virus transmission and mutation.
- disinfection methods include the use of alcohol, 84 disinfectant, etc., but disinfecting the external environment of the human body such as the surrounding air, hands and feet cannot kill viruses that have already entered the human respiratory system, and the only thing the infected people can do is to wait for the viruses to replicate and cause diseases.
- an objective of the present invention is to provide a method for preventing and treating respiratory virus-related diseases by inactivating respiratory viruses.
- the present invention provides the following technical schemes:
- a composition for inhibiting respiratory viruses where acetic acid is used as an active ingredient in the composition.
- the research of the present invention proves that hydrogen ions can inactivate viruses adhering to the human respiratory tract, and acetic acid, as a weak acid, can provide hydrogen ions in a dose of inactivating respiratory viruses at a tolerable concentration, thereby inactivating viruses in the human respiratory tract and preventing and treating respiratory viral infectious diseases.
- the composition includes other auxiliary therapeutic ingredients, such as ethanol, oxygen and anti-allergy ingredients.
- Ethanol can help inactivate viruses and bacteria and can also help relieve the sensory stimulation of the patient caused by acetic acid.
- acetic acid when used for treatment, medical oxygen is mixed to increase the blood oxygen concentration of the patient to strengthen the cardiopulmonary function of the patient, thereby improving the effect of inactivating respiratory viruses.
- an inhalant for inhibiting respiratory viruses is provided, where the inhalant includes the composition according to the first aspect.
- the inhalant of the present invention also includes a composition scheme containing anti-allergy ingredients. Due to individual differences, different people have different tolerances to the ingredients of the above composition. In order to eliminate the possibility of drug allergy and ensure the safety of medication, the inhalant also includes anti-allergy ingredients.
- a respiratory virus prevention and treatment method is provided, where the prevention and treatment method includes inhalation of the inhalant for inhibiting respiratory viruses according to the second aspect.
- a novel coronavirus pneumonia prevention and treatment method is provided, where the method includes the steps of the respiratory virus prevention and treatment method according to the third aspect.
- novel coronavirus pneumonia treatment method provided by the present invention includes the use of the inhalant in combination with anti-novel coronavirus pneumonia drugs, where ⁇ -interferon and the like can be mixed with the inhalant and administrated in an inhalation way; or oral administration or intravenous injection of other anti-novel coronavirus pneumonia drugs is carried out while the inhalant is used for treatment.
- composition according to the first aspect in inhibiting fungi and/or bacteria in vitro is provided.
- composition provided by the present invention can also be applied in inhibiting fungi and bacteria in vitro and in the respiratory tract to prevent fungi or bacteria from adhering to the surface of the skin or respiratory tract to cause diseases.
- the method for preventing respiratory fungi and bacteria is the same as that of the third aspect.
- the method for inhibiting fungi and bacteria on the skin surface includes the use of the high-temperature steam described in the second aspect to fumigate the skin surface.
- composition and inhalant provided by the present invention also have a good effect of killing viruses entering the respiratory system, and can be used for prevention and treatment as well as environmental disinfection. It is proved through experiments that those who use this method for disinfection for about 3 minutes once per day will not be infected with the novel coronavirus; and those who have been infected with the novel coronavirus will recover within 4 days by using this method at the early stage.
- the inhalant mentioned in the present invention has extremely low costs. According to the current price level, each person can be protected from infection with only RMB 0.1 yuan per day, and each patient can be cured with less than RMB 10 yuan.
- the inhalation disinfection method mentioned in the present invention does not have any toxic or side effects on the human body.
- the high-temperature hydrogen ions in the human body can be reduced to normal body temperature in about 0.1 second, form weakly acidic acetic acid with acetate ions, and be excreted with the sputum.
- the present invention provides an inhalant for inhibiting respiratory viruses and a treatment method.
- a composition for inhibiting respiratory viruses where acetic acid is used as an active ingredient in the composition.
- the effects of inhibiting respiratory viruses of the present invention include directly inhibiting or killing viruses, reducing virus activity, interfering with virus adherence, preventing viruses from entering cells, inhibiting virus transcription and copying processes or inhibiting virus release.
- the state in which acetic acid inhibits the activity of respiratory viruses is a steam state, specifically, a high-temperature steam state of an acetic acid solution; that is to say, in the composition, the active ingredient for inhibiting respiratory viruses is high-temperature steam of an acetic acid solution.
- composition of the present invention is administered by inhalation. Based on this administration method, the above composition can directly act on viruses adhered to the respiratory tract and oral mucosa surface, and has a direct inactivating effect, which is better than the effect of inactivating viruses in the interior and interlayer of respiratory mucosal cells.
- the steam acting on viruses is at 50° C. or above.
- the composition also includes one or any mixture of ethanol and oxygen.
- the oxygen is medical oxygen.
- the composition includes acetic acid.
- the composition includes acetic acid and oxygen.
- the composition includes acetic acid and ethanol.
- the composition includes acetic acid, oxygen and ethanol.
- the composition also includes anti-inflammatory drugs, antiviral drugs and/or immunomodulatory drugs.
- an inhalant for inhibiting respiratory viruses is provided, where the inhalant includes the composition according to the first aspect.
- the inhalant includes an acetic acid solution, and the concentration of the acetic acid solution is 0.01%-10% (mass fraction).
- the inhalant includes a mixed solution of acetic acid and ethanol.
- the concentration of acetic acid is 0.01%-10% (mass fraction)
- the concentration of ethanol is 0.01%-10% (mass fraction).
- the inhalant further includes oxygen.
- the inhalant includes high-temperature steam of an acetic acid aqueous solution and oxygen.
- the high-temperature steam of the acetic acid aqueous solution and oxygen in the inhalant are not doped with each other and are inhaled in a certain use order.
- the steam of the acetic acid aqueous solution and oxygen are mixed in a certain volume ratio and inhaled for use at the same time.
- the inhalant includes high-temperature steam of an acetic acid and ethanol aqueous solution and oxygen.
- the high-temperature steam of the acetic acid and ethanol aqueous solution and oxygen are not doped with each other and are inhaled in a certain use order.
- the high-temperature steam of the acetic acid and ethanol aqueous solution and oxygen are mixed in a certain volume ratio and inhaled for use at the same time.
- the inhalant further includes anti-allergy ingredients.
- the anti-allergy ingredients include antihistamine drugs, allergic reaction mediator release-blocking drugs, histamine desensitizers, leukotriene receptor antagonists, drugs for inhibiting antigen-antibody reactions and drugs for alleviating or controlling allergy symptoms.
- antihistamine drugs include but are not limited to diphenhydramine, promethazine and chlorpheniramine.
- allergic reaction mediator release-blocking drugs include but are not limited to sodium cromoglycate and ketotifen.
- histamine desensitizers include but are not limited to betahistine, small-dose histamine diluent and dust mite injection.
- the leukotriene receptor antagonists include but are not limited to montelukast and zafirlukast.
- the drugs for inhibiting antigen-antibody reactions are adrenal glucocorticoids, immunosuppressants and the like.
- the drugs for alleviating or controlling allergy symptoms include but are not limited to smooth muscle antispasmodics such as salbutamol and drugs for reducing edema caused by allergies such as calcium gluconate.
- the anti-allergy ingredients are added to the acetic acid and ethanol aqueous solution according to the clinical use concentration, where the leukotriene receptor antagonists such as montelukast and zafirlukast are more suitable for respiratory allergies and are added to the inhalant as more preferred ingredients.
- the high-temperature steam of an acetic acid, ethanol and anti-allergy agent aqueous solution and oxygen are mixed in a certain volume ratio and inhaled for use at the same time.
- a respiratory virus prevention and treatment method is provided, where the prevention and treatment method includes inhalation of the inhalant for inhibiting respiratory viruses according to the second aspect.
- the respiratory viruses include but are not limited to rhinoviruses, coronaviruses, enteroviruses, adenoviruses and respiratory syncytial viruses.
- the coronaviruses include but are not limited to SARS-CoV and 2019-nCoV.
- the inhalation temperature of the inhalant is relatively high and can be tolerated by the human body. It is proved by the present invention that the inhalation temperature of the inhalant is 50° C. or above.
- a method of using the inhalant is as follows: a part of the inhalant which is in liquid form at room temperature is heated and boiled to produce steam, a patient needs to continuously inhale the steam for a period of time, and the inhalation temperature of the steam should be maintained at 50° C. or above with the high temperature that the human body can withstand as the upper limit.
- the inhalation time of the steam is 1-20 min/d.
- the concentration of acetic acid in the inhalant is determined according to the tolerance of a patient. It is recommended to use a 0.01%-2% acetic acid solution for children and elderly patients and an acetic acid solution with the concentration of 0.5%-5% for adult patients to achieve the best therapeutic effects.
- the inhalant is a mixed aqueous solution of acetic acid and ethanol, where the ratio of acetic acid to ethanol is 1:(0.1-2).
- the inhalant is an acetic acid aqueous solution
- the acetic acid aqueous solution is heated to boil, and a patient continuously inhales the steam of the acetic acid aqueous solution at 50° C. or above for 1-10 min for treatment.
- the inhalant is an acetic acid and ethanol aqueous solution.
- the acetic acid and ethanol aqueous solution is heated to boil, and a patient continuously inhales the steam of the acetic acid and ethanol aqueous solution at 50° C. or above for 5-10 min for treatment, where in the acetic acid and ethanol aqueous solution, the mass ratio of acetic acid to ethanol is 1:1.
- inhalation of oxygen is also included for auxiliary therapy.
- the oxygen is medical oxygen.
- the patient inhales the steam and oxygen for a period of time respectively, or mixes the steam and oxygen before inhalation.
- the prevention and treatment method also includes using other drugs at the same time for treatment.
- the other drugs include but are not limited to neuraminidase inhibitors, steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, antibiotics, immunostimulants, immunomodulators, nucleoside antiviral agents, nucleotide antiviral agents, anti-fibrosis drugs, caspase inhibitors, creatinine 5′-monophosphate dehydrogenase inhibitors and viral enzyme inhibitors.
- a novel coronavirus pneumonia prevention and treatment method is provided, where the method includes the steps of the respiratory virus prevention and treatment method according to the third aspect.
- the prevention and treatment method is applied to prevention or treatment of novel coronavirus pneumonia.
- the prevention and treatment method also includes a method of combined use with anti-novel coronavirus pneumonia drugs.
- the anti-novel coronavirus drugs include but are not limited to ⁇ -interferon, lopinavir, ritonavir, ribavirin, favipiravir, chloroquine phosphate or remdesivir.
- the novel coronavirus often enters the host body by adhering to the eyes, nose, mouth, hands and other parts of human to cause diseases.
- the eyes, nose, mouth and other parts which are difficult to disinfect can be effectively disinfected.
- a user only needs to move his or her face close to the steam of the acetic acid solution and inhale the steam for a period of time to achieve a comprehensive disinfection effect on the eyes, nose and mouth.
- a face mask inhalation method can also be adopted. After mixed with oxygen, the acetic acid steam is introduced into a face mask to disinfect the entire face.
- composition according to the first aspect in inhibiting fungi and/or bacteria in vitro is provided.
- the part in vitro includes the skin surface and the surface of a cavity communicating with the outside; further preferably, the part in vitro includes the skin surface and the respiratory tract.
- the fungi include common superficial Bacillus fungi on the skin surface such as Trichophyton, Epidermophyton and Microsporum , deep infection fungi such as Candidas and Cryptococcus neoformans , and other pulmonary system infectious fungi such as Pneumocystis.
- the bacteria are preferably respiratory bacteria, which include but are not limited to one or any mixture of Mycobacterium tuberculosis, Corynebacterium diphtheria, Legionella pneumophila, Haemophilus influenzae, Bordetella pertussis, Mycoplasma pneumoniae and Chlamydia pneumoniae.
- an inhalant for inhibiting respiratory viruses was provided.
- the inhalant was a 2.5% acetic acid solution.
- a use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale the steam produced during boiling and fresh air in turn, the inhalation temperature of the steam should be kept at 50° C. or above, and the patient needed to inhale the steam at high temperature as far as the he/she can tolerate.
- the treatment frequency for preventing respiratory viruses was once a day, and the inhalation time was 3 min.
- the treatment frequency for treatment of diseases caused by respiratory viruses was three times a day, and the recommended inhalation time was 5 min each time.
- an inhalant for inhibiting respiratory viruses was provided.
- the inhalant was a 2.5% mixed aqueous solution of acetic acid and ethanol (the concentrations of acetic acid and ethanol were both 2.5%).
- a use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale the steam produced during boiling and fresh air in turn, and the inhalation temperature of the steam should be kept at 50° C. or above.
- the treatment frequency for preventing respiratory viruses was once a day, and the inhalation time was 3 min.
- the treatment frequency for treatment of diseases caused by respiratory viruses was 3-6 times a day, and the recommended inhalation time was 5 min each time.
- an inhalant for inhibiting respiratory viruses was provided.
- the inhalant included medical oxygen and a 2.5% mixed aqueous solution of acetic acid and ethanol (the concentrations of acetic acid and ethanol were both 2.5%).
- a use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale a mixture of the steam produced during boiling and the medical oxygen for a period of time, and the inhalation temperature of the steam should be kept at 50° C. or above.
- the treatment frequency for preventing respiratory viruses was once a day, and the vapor inhalation time was 3 min.
- the treatment frequency for treatment of diseases caused by respiratory viruses was three times a day, and the recommended steam inhalation time was 5 min each time.
- an inhalant for prevention and treatment of novel coronary pneumonia included medical oxygen and a 2.5% mixed aqueous solution of acetic acid and ethanol (the concentrations of acetic acid and ethanol were both 2.5%).
- a use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale the steam produced during boiling and the medical oxygen in turn, and the inhalation temperature of the steam should be kept at 50° C. or above.
- the treatment frequency for preventing novel coronary pneumonia was once a day, and the steam inhalation time was 3 min.
- the treatment frequency for treatment of novel coronary pneumonia was three times a day, and the recommended steam inhalation time was 5 min each time.
- a novel coronary pneumonia treatment method was provided. Different from the method in Embodiment 4, in this embodiment, atomized ⁇ -interferon was also inhaled at the same time.
- an inhalant for prevention and treatment of novel coronary pneumonia included medical oxygen and a 2.5% mixed aqueous solution of acetic acid, ethanol and montelukast (the concentrations of acetic acid and ethanol were both 2.5%).
- a use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale the steam produced during boiling and the medical oxygen in turn, and the inhalation temperature of the steam should be kept at 50° C. or above.
- the treatment frequency for preventing novel coronary pneumonia was once a day, and the steam inhalation time was 3 min.
- the treatment frequency for treatment of novel coronary pneumonia was three times a day, and the recommended steam inhalation time was 5 min each time.
- an inhalant for prevention and treatment of respiratory bacterial and fungal infections was provided.
- the inhalant included medical oxygen and a 2.5% mixed aqueous solution of acetic acid, ethanol and montelukast (the concentrations of acetic acid and ethanol were both 2.5%).
- a use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale the steam produced during boiling and the medical oxygen in turn, and the inhalation temperature of the steam should be kept at 50° C. or above.
- the treatment frequency for preventing bacterial and fungal infections was once a day, and the steam inhalation time was 3 min.
- the treatment frequency for treatment of bacterial and fungal infections was three times a day, and the recommended steam inhalation time was 5 min each time.
- the control group was treated with a conventional novel coronary pneumonia treatment method
- the experimental group was treated with the method according to Embodiment 1.
- the cure rates of the patients in the control group and the experimental group were tested respectively according to the provisions in the Diagnosis and Treatment Plan for Pneumonia Infected by Novel Coronavirus (Trial Fifth Edition): the body temperature returns to normal for 3 days or more, respiratory symptoms are improved significantly, lung imaging shows obvious absorption of inflammation, and two consecutive nucleic acid tests for respiratory pathogens are negative (the sampling interval is at least 1 day).
Abstract
Description
- The present invention belongs to the technical field of biomedicine, and specifically relates to a composition for inhibiting respiratory viruses and a respiratory virus prevention and treatment method.
- Disclosure of the related art information is only intended to increase the understanding of the overall background of the present invention, and is not necessarily regarded as an acknowledgement or in any form suggesting that the information constitutes the prior art known to those of ordinary skill in the art.
- As one of the common clinical diseases, respiratory viral infectious disease has complex etiology and high viral variability, which is prone to outbreaks in the population. At present, there are as many as 100-200 kinds of viruses that can cause respiratory infections, which can be divided into RNA viruses and DNA viruses. The most common pathogenic viruses include influenza viruses, parainfluenza viruses, respiratory syncytial viruses, adenoviruses, rhinoviruses and coronaviruses. In recent years, there have been several new highly pathogenic viruses which mainly infect the respiratory tract, such as SARS coronavirus (SARS-CoV), H5N1 human avian influenza A virus and 2009 novel H1N1 influenza A virus. Due to the aging society, organ transplantation, the application of immunosuppressants in immunity-related diseases, the increase in the incidence of human acquired immunodeficiency syndromes, the increasing number of patients and other factors, the incidence of new or recurring respiratory viral infections is increasing, and the fatality rate of some viral infections is extremely high. Therefore, this type of diseases has become a public health problem which cannot be ignored.
- Novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19) refers to the pneumonia caused by the 2019 novel coronavirus infection. The structure of the novel coronavirus includes a protein coat and a single-stranded RNA carrying genetic materials. This simple structure reduces the difficulty of replication of the novel coronavirus and increases the spread of the virus. The single strand makes the novel coronavirus more likely to mutate, thereby increasing the difficulty of drug treatment. The main transmission routes of the novel coronavirus include respiratory droplet transmission, contact transmission, aerosol and fecal-oral transmission. Epidemiological investigations show that people of all ages may be infected, and most victims are adults, among whom the elderly, the weak and the sick seem to be more likely to be infected.
- Respiratory viral infections are clinically very common, but there are few corresponding therapeutic drugs. Commonly used clinical antiviral drugs mainly include oseltamivir, amantadines, ribavirin, ganciclovir and Chinese patent medicines containing Scutellaria baicalensis or andrographolide, and the main prevention methods for respiratory viral infections are vaccine prevention, personal hygiene, disinfection of the external environment and the like. The current treatment and prevention drugs cannot fully meet the current needs for the treatment of respiratory viral infections, and the speed of research and development of related drugs is far lower than the speed of virus transmission and mutation. Currently commonly used disinfection methods include the use of alcohol, 84 disinfectant, etc., but disinfecting the external environment of the human body such as the surrounding air, hands and feet cannot kill viruses that have already entered the human respiratory system, and the only thing the infected people can do is to wait for the viruses to replicate and cause diseases.
- In view of the research background above, an objective of the present invention is to provide a method for preventing and treating respiratory virus-related diseases by inactivating respiratory viruses. In order to achieve this objective, the present invention provides the following technical schemes:
- According to a first aspect of the present invention, a composition for inhibiting respiratory viruses is provided, where acetic acid is used as an active ingredient in the composition.
- The research of the present invention proves that hydrogen ions can inactivate viruses adhering to the human respiratory tract, and acetic acid, as a weak acid, can provide hydrogen ions in a dose of inactivating respiratory viruses at a tolerable concentration, thereby inactivating viruses in the human respiratory tract and preventing and treating respiratory viral infectious diseases.
- In addition, the composition includes other auxiliary therapeutic ingredients, such as ethanol, oxygen and anti-allergy ingredients. Ethanol can help inactivate viruses and bacteria and can also help relieve the sensory stimulation of the patient caused by acetic acid. In addition, when acetic acid is used for treatment, medical oxygen is mixed to increase the blood oxygen concentration of the patient to strengthen the cardiopulmonary function of the patient, thereby improving the effect of inactivating respiratory viruses.
- According to a second aspect of the present invention, an inhalant for inhibiting respiratory viruses is provided, where the inhalant includes the composition according to the first aspect.
- The inhalant of the present invention also includes a composition scheme containing anti-allergy ingredients. Due to individual differences, different people have different tolerances to the ingredients of the above composition. In order to eliminate the possibility of drug allergy and ensure the safety of medication, the inhalant also includes anti-allergy ingredients.
- According to a third aspect of the present invention, a respiratory virus prevention and treatment method is provided, where the prevention and treatment method includes inhalation of the inhalant for inhibiting respiratory viruses according to the second aspect.
- It is believed through the research of the present invention that in the acetic acid steam at high temperature, acetic acid molecules can ionize to produce more hydrogen ions, and hydrogen ions are the main virus inactivating substances. As the temperature of the steam increases, the ionization output is also increased, and the kinetic energy is also increased substantially. Therefore, increasing the inhalation temperature of the steam as much as possible can further improve the effect of inactivating viruses in the respiratory tract.
- According to a fourth aspect of the present invention, a novel coronavirus pneumonia prevention and treatment method is provided, where the method includes the steps of the respiratory virus prevention and treatment method according to the third aspect.
- In addition, the novel coronavirus pneumonia treatment method provided by the present invention includes the use of the inhalant in combination with anti-novel coronavirus pneumonia drugs, where α-interferon and the like can be mixed with the inhalant and administrated in an inhalation way; or oral administration or intravenous injection of other anti-novel coronavirus pneumonia drugs is carried out while the inhalant is used for treatment.
- According to a fifth aspect of the present invention, application of the composition according to the first aspect in inhibiting fungi and/or bacteria in vitro is provided.
- The composition provided by the present invention can also be applied in inhibiting fungi and bacteria in vitro and in the respiratory tract to prevent fungi or bacteria from adhering to the surface of the skin or respiratory tract to cause diseases. The method for preventing respiratory fungi and bacteria is the same as that of the third aspect. The method for inhibiting fungi and bacteria on the skin surface includes the use of the high-temperature steam described in the second aspect to fumigate the skin surface.
- The beneficial effects of one or more of the above technical schemes are:
- The composition and inhalant provided by the present invention also have a good effect of killing viruses entering the respiratory system, and can be used for prevention and treatment as well as environmental disinfection. It is proved through experiments that those who use this method for disinfection for about 3 minutes once per day will not be infected with the novel coronavirus; and those who have been infected with the novel coronavirus will recover within 4 days by using this method at the early stage.
- In addition, the inhalant mentioned in the present invention has extremely low costs. According to the current price level, each person can be protected from infection with only RMB 0.1 yuan per day, and each patient can be cured with less than RMB 10 yuan.
- The inhalation disinfection method mentioned in the present invention does not have any toxic or side effects on the human body. After killing the viruses, the high-temperature hydrogen ions in the human body can be reduced to normal body temperature in about 0.1 second, form weakly acidic acetic acid with acetate ions, and be excreted with the sputum.
- It should be noted that, the following detailed descriptions are exemplary, and are intended to provide a further description to the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs.
- It should be noted that terms used herein are only for the purpose of describing specific implementations and are not intended to limit the exemplary implementations of the present invention. As used herein, the singular form is intended to include the plural form, unless the context clearly indicates otherwise. In addition, it should further be understood that terms “comprise” and/or “include” used in this specification indicate that there are features, steps, operations, devices, components, and/or combinations thereof.
- As introduced in the related art, in view of the current situation that anti-respiratory virus drugs cannot satisfy clinical applications, in order to solve the above technical problems, the present invention provides an inhalant for inhibiting respiratory viruses and a treatment method.
- According to a first aspect of the present invention, a composition for inhibiting respiratory viruses is provided, where acetic acid is used as an active ingredient in the composition.
- The effects of inhibiting respiratory viruses of the present invention include directly inhibiting or killing viruses, reducing virus activity, interfering with virus adherence, preventing viruses from entering cells, inhibiting virus transcription and copying processes or inhibiting virus release.
- Preferably, the state in which acetic acid inhibits the activity of respiratory viruses is a steam state, specifically, a high-temperature steam state of an acetic acid solution; that is to say, in the composition, the active ingredient for inhibiting respiratory viruses is high-temperature steam of an acetic acid solution.
- It has been proved that the composition of the present invention is administered by inhalation. Based on this administration method, the above composition can directly act on viruses adhered to the respiratory tract and oral mucosa surface, and has a direct inactivating effect, which is better than the effect of inactivating viruses in the interior and interlayer of respiratory mucosal cells.
- Further preferably, the steam acting on viruses is at 50° C. or above.
- Preferably, the composition also includes one or any mixture of ethanol and oxygen.
- Further, the oxygen is medical oxygen.
- In some implementations of the present invention, the composition includes acetic acid.
- In some implementations of the present invention, the composition includes acetic acid and oxygen.
- In some implementations of the present invention, the composition includes acetic acid and ethanol.
- In some implementations of the present invention, the composition includes acetic acid, oxygen and ethanol.
- Preferably, the composition also includes anti-inflammatory drugs, antiviral drugs and/or immunomodulatory drugs.
- According to a second aspect of the present invention, an inhalant for inhibiting respiratory viruses is provided, where the inhalant includes the composition according to the first aspect.
- Preferably, the inhalant includes an acetic acid solution, and the concentration of the acetic acid solution is 0.01%-10% (mass fraction).
- Preferably, the inhalant includes a mixed solution of acetic acid and ethanol. In the mixed solution, the concentration of acetic acid is 0.01%-10% (mass fraction), and the concentration of ethanol is 0.01%-10% (mass fraction).
- Preferably, the inhalant further includes oxygen.
- Further preferably, the inhalant includes high-temperature steam of an acetic acid aqueous solution and oxygen.
- In some specific implementations of the above preferred technical schemes, the high-temperature steam of the acetic acid aqueous solution and oxygen in the inhalant are not doped with each other and are inhaled in a certain use order.
- In some other implementations, the steam of the acetic acid aqueous solution and oxygen are mixed in a certain volume ratio and inhaled for use at the same time.
- Further preferably, the inhalant includes high-temperature steam of an acetic acid and ethanol aqueous solution and oxygen.
- In some specific implementations of the above preferred technical schemes, the high-temperature steam of the acetic acid and ethanol aqueous solution and oxygen are not doped with each other and are inhaled in a certain use order.
- In some other implementations, the high-temperature steam of the acetic acid and ethanol aqueous solution and oxygen are mixed in a certain volume ratio and inhaled for use at the same time.
- Preferably, the inhalant further includes anti-allergy ingredients.
- Further preferably, the anti-allergy ingredients include antihistamine drugs, allergic reaction mediator release-blocking drugs, histamine desensitizers, leukotriene receptor antagonists, drugs for inhibiting antigen-antibody reactions and drugs for alleviating or controlling allergy symptoms.
- Further, the antihistamine drugs include but are not limited to diphenhydramine, promethazine and chlorpheniramine.
- Further, the allergic reaction mediator release-blocking drugs include but are not limited to sodium cromoglycate and ketotifen.
- Further, the histamine desensitizers include but are not limited to betahistine, small-dose histamine diluent and dust mite injection.
- Further, the leukotriene receptor antagonists include but are not limited to montelukast and zafirlukast.
- Further, the drugs for inhibiting antigen-antibody reactions are adrenal glucocorticoids, immunosuppressants and the like.
- Further, the drugs for alleviating or controlling allergy symptoms include but are not limited to smooth muscle antispasmodics such as salbutamol and drugs for reducing edema caused by allergies such as calcium gluconate.
- In the above technical schemes regarding the anti-allergy ingredients, the anti-allergy ingredients are added to the acetic acid and ethanol aqueous solution according to the clinical use concentration, where the leukotriene receptor antagonists such as montelukast and zafirlukast are more suitable for respiratory allergies and are added to the inhalant as more preferred ingredients.
- In some specific implementations of the above preferred technical schemes, in the inhalant, the high-temperature steam of an acetic acid, ethanol and anti-allergy agent aqueous solution and oxygen are mixed in a certain volume ratio and inhaled for use at the same time.
- According to a third aspect of the present invention, a respiratory virus prevention and treatment method is provided, where the prevention and treatment method includes inhalation of the inhalant for inhibiting respiratory viruses according to the second aspect.
- Preferably, the respiratory viruses include but are not limited to rhinoviruses, coronaviruses, enteroviruses, adenoviruses and respiratory syncytial viruses.
- Further preferably, the coronaviruses include but are not limited to SARS-CoV and 2019-nCoV.
- Preferably, the inhalation temperature of the inhalant is relatively high and can be tolerated by the human body. It is proved by the present invention that the inhalation temperature of the inhalant is 50° C. or above.
- Further preferably, a method of using the inhalant is as follows: a part of the inhalant which is in liquid form at room temperature is heated and boiled to produce steam, a patient needs to continuously inhale the steam for a period of time, and the inhalation temperature of the steam should be maintained at 50° C. or above with the high temperature that the human body can withstand as the upper limit.
- In some implementations of the above preferred technical schemes, the inhalation time of the steam is 1-20 min/d.
- In some implementations of the above preferred technical schemes, the concentration of acetic acid in the inhalant is determined according to the tolerance of a patient. It is recommended to use a 0.01%-2% acetic acid solution for children and elderly patients and an acetic acid solution with the concentration of 0.5%-5% for adult patients to achieve the best therapeutic effects.
- In some implementations of the above preferred technical schemes, the inhalant is a mixed aqueous solution of acetic acid and ethanol, where the ratio of acetic acid to ethanol is 1:(0.1-2).
- In an implementation with a good effect of the present invention, the inhalant is an acetic acid aqueous solution, the acetic acid aqueous solution is heated to boil, and a patient continuously inhales the steam of the acetic acid aqueous solution at 50° C. or above for 1-10 min for treatment.
- In an implementation with a good effect of the present invention, the inhalant is an acetic acid and ethanol aqueous solution. The acetic acid and ethanol aqueous solution is heated to boil, and a patient continuously inhales the steam of the acetic acid and ethanol aqueous solution at 50° C. or above for 5-10 min for treatment, where in the acetic acid and ethanol aqueous solution, the mass ratio of acetic acid to ethanol is 1:1.
- In the above series of implementations, inhalation of oxygen is also included for auxiliary therapy. The oxygen is medical oxygen. The patient inhales the steam and oxygen for a period of time respectively, or mixes the steam and oxygen before inhalation.
- Preferably, the prevention and treatment method also includes using other drugs at the same time for treatment. The other drugs include but are not limited to neuraminidase inhibitors, steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, antibiotics, immunostimulants, immunomodulators, nucleoside antiviral agents, nucleotide antiviral agents, anti-fibrosis drugs, caspase inhibitors, creatinine 5′-monophosphate dehydrogenase inhibitors and viral enzyme inhibitors.
- According to a fourth aspect of the present invention, a novel coronavirus pneumonia prevention and treatment method is provided, where the method includes the steps of the respiratory virus prevention and treatment method according to the third aspect.
- Preferably, the prevention and treatment method is applied to prevention or treatment of novel coronavirus pneumonia.
- Preferably, the prevention and treatment method also includes a method of combined use with anti-novel coronavirus pneumonia drugs. The anti-novel coronavirus drugs include but are not limited to α-interferon, lopinavir, ritonavir, ribavirin, favipiravir, chloroquine phosphate or remdesivir.
- The novel coronavirus often enters the host body by adhering to the eyes, nose, mouth, hands and other parts of human to cause diseases. By using the methods of the present invention, the eyes, nose, mouth and other parts which are difficult to disinfect can be effectively disinfected. A user only needs to move his or her face close to the steam of the acetic acid solution and inhale the steam for a period of time to achieve a comprehensive disinfection effect on the eyes, nose and mouth. For users who may be exposed to the novel coronavirus, a face mask inhalation method can also be adopted. After mixed with oxygen, the acetic acid steam is introduced into a face mask to disinfect the entire face.
- According to a fifth aspect of the present invention, application of the composition according to the first aspect in inhibiting fungi and/or bacteria in vitro is provided.
- Preferably, the part in vitro includes the skin surface and the surface of a cavity communicating with the outside; further preferably, the part in vitro includes the skin surface and the respiratory tract.
- The fungi include common superficial Bacillus fungi on the skin surface such as Trichophyton, Epidermophyton and Microsporum, deep infection fungi such as Candidas and Cryptococcus neoformans, and other pulmonary system infectious fungi such as Pneumocystis.
- The bacteria are preferably respiratory bacteria, which include but are not limited to one or any mixture of Mycobacterium tuberculosis, Corynebacterium diphtheria, Legionella pneumophila, Haemophilus influenzae, Bordetella pertussis, Mycoplasma pneumoniae and Chlamydia pneumoniae.
- To make a person skilled in the art understand the technical solutions of the present invention more clearly, the technical solutions of the present invention are described below with reference to specific embodiments.
- In this embodiment, an inhalant for inhibiting respiratory viruses was provided. The inhalant was a 2.5% acetic acid solution. A use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale the steam produced during boiling and fresh air in turn, the inhalation temperature of the steam should be kept at 50° C. or above, and the patient needed to inhale the steam at high temperature as far as the he/she can tolerate.
- The treatment frequency for preventing respiratory viruses was once a day, and the inhalation time was 3 min. The treatment frequency for treatment of diseases caused by respiratory viruses was three times a day, and the recommended inhalation time was 5 min each time.
- In this embodiment, an inhalant for inhibiting respiratory viruses was provided. The inhalant was a 2.5% mixed aqueous solution of acetic acid and ethanol (the concentrations of acetic acid and ethanol were both 2.5%). A use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale the steam produced during boiling and fresh air in turn, and the inhalation temperature of the steam should be kept at 50° C. or above.
- The treatment frequency for preventing respiratory viruses was once a day, and the inhalation time was 3 min. The treatment frequency for treatment of diseases caused by respiratory viruses was 3-6 times a day, and the recommended inhalation time was 5 min each time.
- In this embodiment, an inhalant for inhibiting respiratory viruses was provided. The inhalant included medical oxygen and a 2.5% mixed aqueous solution of acetic acid and ethanol (the concentrations of acetic acid and ethanol were both 2.5%). A use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale a mixture of the steam produced during boiling and the medical oxygen for a period of time, and the inhalation temperature of the steam should be kept at 50° C. or above.
- The treatment frequency for preventing respiratory viruses was once a day, and the vapor inhalation time was 3 min. The treatment frequency for treatment of diseases caused by respiratory viruses was three times a day, and the recommended steam inhalation time was 5 min each time.
- In this embodiment, an inhalant for prevention and treatment of novel coronary pneumonia was provided. The inhalant included medical oxygen and a 2.5% mixed aqueous solution of acetic acid and ethanol (the concentrations of acetic acid and ethanol were both 2.5%). A use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale the steam produced during boiling and the medical oxygen in turn, and the inhalation temperature of the steam should be kept at 50° C. or above.
- The treatment frequency for preventing novel coronary pneumonia was once a day, and the steam inhalation time was 3 min. The treatment frequency for treatment of novel coronary pneumonia was three times a day, and the recommended steam inhalation time was 5 min each time.
- In this embodiment, a novel coronary pneumonia treatment method was provided. Different from the method in Embodiment 4, in this embodiment, atomized α-interferon was also inhaled at the same time.
- In this embodiment, an inhalant for prevention and treatment of novel coronary pneumonia was provided. The inhalant included medical oxygen and a 2.5% mixed aqueous solution of acetic acid, ethanol and montelukast (the concentrations of acetic acid and ethanol were both 2.5%). A use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale the steam produced during boiling and the medical oxygen in turn, and the inhalation temperature of the steam should be kept at 50° C. or above.
- The treatment frequency for preventing novel coronary pneumonia was once a day, and the steam inhalation time was 3 min. The treatment frequency for treatment of novel coronary pneumonia was three times a day, and the recommended steam inhalation time was 5 min each time.
- In this embodiment, an inhalant for prevention and treatment of respiratory bacterial and fungal infections was provided. The inhalant included medical oxygen and a 2.5% mixed aqueous solution of acetic acid, ethanol and montelukast (the concentrations of acetic acid and ethanol were both 2.5%). A use method of the inhalant was as follows: the inhalant was heated to boil, a patient needed to inhale the steam produced during boiling and the medical oxygen in turn, and the inhalation temperature of the steam should be kept at 50° C. or above.
- The treatment frequency for preventing bacterial and fungal infections was once a day, and the steam inhalation time was 3 min. The treatment frequency for treatment of bacterial and fungal infections was three times a day, and the recommended steam inhalation time was 5 min each time.
- 40 patients infected with novel coronary pneumonia were collected and randomly divided into two groups. The control group was treated with a conventional novel coronary pneumonia treatment method, and the experimental group was treated with the method according to Embodiment 1. After treatment for a period of time, the cure rates of the patients in the control group and the experimental group were tested respectively according to the provisions in the Diagnosis and Treatment Plan for Pneumonia Infected by Novel Coronavirus (Trial Fifth Edition): the body temperature returns to normal for 3 days or more, respiratory symptoms are improved significantly, lung imaging shows obvious absorption of inflammation, and two consecutive nucleic acid tests for respiratory pathogens are negative (the sampling interval is at least 1 day).
- From 2019 to 2020, 20 influenza patients were recruited as volunteers and the treatment method described in Embodiment 1 was used for treatment. A treatment course was 3 days, the cure rate was 100%, and the cure time was one treatment course, where the temperature of patients with high fever can drop to normal level on the second day of treatment.
- The foregoing descriptions are merely preferred embodiments of the present invention but are not intended to limit the present invention. The present invention may include various modifications and changes for a person skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention shall fall within the protection scope of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/034,787 US20220096407A1 (en) | 2020-09-28 | 2020-09-28 | Composition for inhibiting respiratory viruses and respiratory virus prevention and treatment method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/034,787 US20220096407A1 (en) | 2020-09-28 | 2020-09-28 | Composition for inhibiting respiratory viruses and respiratory virus prevention and treatment method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220096407A1 true US20220096407A1 (en) | 2022-03-31 |
Family
ID=80822183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/034,787 Abandoned US20220096407A1 (en) | 2020-09-28 | 2020-09-28 | Composition for inhibiting respiratory viruses and respiratory virus prevention and treatment method |
Country Status (1)
Country | Link |
---|---|
US (1) | US20220096407A1 (en) |
-
2020
- 2020-09-28 US US17/034,787 patent/US20220096407A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
International Journal of Basic and Clinical Pharmacology (https://www.ijbcp.com/index.php/ijbcp/article/view/4313) table of contents pdf, published 09-22-2020 (Year: 2020) * |
Islam (Possible use of alcohol vapors by inhalation in the treatment of COVID-19 in clinical ill patients, Int J Basic Clin Pharamacol. 2020 Oct; 9(10):1627-1628). published 9/22/2020 as indicated by the table of contents (Year: 2020) * |
Mary et. al. (Therapeutic Options for Coronavirus Disease 2019 (COVID-19) Modulation of Type I Interferon Response as a Promising Strategy?, Frontiers in Public Health, May 2020, Vol 8, Article 185). (Year: 2020) * |
Pianta (Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19, European Archives of Oto-Rhino-Laryngology (2020) 277:2921-2924). published 5/24/2020. (Year: 2020) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Neto et al. | A randomized controlled trial of mist in the acute treatment of moderate croup | |
KR101437708B1 (en) | Antiviral composition and method of use | |
Go et al. | Potential role of xylitol plus grapefruit seed extract nasal spray solution in COVID-19: case series | |
WO2022111497A1 (en) | Application of iodine in preparation of drugs for preventing and treating respiratory tract infectious diseases | |
JP2023526547A (en) | Certain drug systems, methods, and uses for reducing viral replication in airway mucosa | |
US20230158259A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
EP3892275A1 (en) | Aerosolization of hcq or its metabolites for the treatment of lung infections | |
EP4218726A1 (en) | Composition for inhibiting respiratory virus and respiratory virus prevention and treatment method | |
JP7369523B2 (en) | Treatment of moderate to severe influenza | |
CN105853999A (en) | Interferon lambda-containing aerosol inhalant | |
CN103169754A (en) | Traditional Chinese medicinal composition for treating asthma | |
Liss et al. | Ribavirin aerosol in the elderly | |
US20220096407A1 (en) | Composition for inhibiting respiratory viruses and respiratory virus prevention and treatment method | |
Krasno et al. | Inhalation of penicillin dust | |
Hayden et al. | Comparative therapeutic effect of aerosolized and oral rimantadine HC1 in experimental human influenza A virus infection | |
US20220133785A1 (en) | THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES | |
CN102188574B (en) | One treats bronchitic Chinese medicine composition of influenza A virus and preparation method thereof | |
US20230030607A1 (en) | Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases | |
Hayden et al. | Amantadine aerosols in normal volunteers: pharmacology and safety testing | |
IL298543A (en) | Azelastine as antiviral treatment | |
TW201016215A (en) | Compositions and uses of antiviral active pharmaceutical agents | |
EP4125814A1 (en) | Iodine compounds for treating respiratory pathogens | |
US20220273594A1 (en) | Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections | |
Misra | A short review on important drugs under clinical trial against Covid-19 | |
JP2002030000A (en) | Fundamental treatment for common cold |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ZONGZHAN DU, CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DU, ZONGZHAN;GAO, QI;SIGNING DATES FROM 20201106 TO 20201107;REEL/FRAME:054539/0543 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |